Hematological Neoplasms
In recent years, the field of oncology has witnessed groundbreaking advancements, particularly in the realm of CAR-T (Chimeric Antigen Receptor T-cell) therapy.
**Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital** In the field of cancer treatment, China has achieved groundbreaking success with CAR-T cell therapy, especially in treating relapsed or refractory lymphoma. Today, we share the story of one patient whose life was transformed through this revolutionary treatment Read More
#### New Breakthrough in CAR-T Cell Research in China: Type 2 T Cell Function Supports Long-term Leukemia Remission #CAR-T #Leukemia #Type2TCells #ALL #GATA3 In recent years, China has achieved significant progress in CAR-T cell therapy, particularly in treating acute lymphoblastic leukemia (ALL). CD19-targeted CAR-T cell therapy has provided new hope for curing patients with relapsed or refractory Read More
**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)** #CAR-T #DLBCL #Lymphoma #CARTtherapy #RRDLBCL #Patientstory #CD19 In the field of cancer treatment, China has made remarkable strides in CAR-T cell therapy, especially in the fight against relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Read More
### APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL) #CAR-T #CNSL #ASCT #APBMT2024 #CARTtherapy #CentralNervousSystemLymphoma #Lymphoma #RRCNSL #APBMT In the treatment of relapsed or refractory central nervous system lymphoma (R/R CNSL), Chinese CAR-T therapy is pioneering new directions worldwide. Conventional treatments for this disease have shown limited effectiveness, particularly when autologous stem Read More
Groundbreaking Chinese CAR-T Research: CD5 CAR-T Therapy Brings New Hope for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) Relapsed or refractory acute T-cell lymphoblastic leukemia (r/r T-ALL) has long lacked effective treatment options, with a poor prognosis. Although CD7 CAR-T therapy has shown some efficacy, many patients experience relapse due to CD7 antigen loss. #CAR-T #TALL #ALL #CARTtherapy #leukemia Read More
**Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage** #CAR_TTherapy #B_ALL #DonorCAR_T #CAR_T #ALL #ChinaCART #CD19 #alloHSCT In recent years, China has made significant strides in CAR-T cell therapy, particularly in treating B-cell acute lymphoblastic leukemia (B-ALL). Donor-derived CAR-T therapy has shown promising efficacy for B-ALL patients who Read More
**The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients** #CARTTherapy #CART #MultipleMyeloma #BloodCancer #patientstory China’s CAR-T cell therapy has emerged as a highly effective and proactive option for treating relapsed and refractory multiple myeloma, bringing new hope to patients facing limited treatment options. This innovative therapy has shown significant effectiveness in clinical Read More